- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Revised cholesterol treatment guidelines
The National Cholesterol Education Program made several changes to its adult treatment panel report on the detection, evaluation and treatment of high blood cholesterol.
The National Cholesterol Education Program made several changes to its adult treatment panel report on the detection, evaluation and treatment of high blood cholesterol.
The revised guidelines recommend that physicians increase emphasis on coronary heart disease risk status as the guide to the type and intensity of cholesterol-lowering therapy. Patients with evident coronary heart disease are at highest risk and a therapeutic goal of low-density lipoproteins of less than 100 mg/dL is recommended. Age (45 years or older for men, and 55 years or older for women) was added to the list of major risk factors.
The guidelines recommend that physicians delay the use of drug therapy in most young men 35 years and younger and in pre-menopausal women with moderately high low-density lipoproteins (160 mg/dL to 220 mg/dL) who are otherwise at low risk for coronary heart disease. However, the guidelines encourage physicians to consider high-risk, post-menopausal women and high-risk elderly with high blood cholesterol as candidates for drug therapy.
The guidelines also urge physicians to pay more attention to low high-density lipoprotein levels as coronary heart disease risk factors. Physicians should add high-density lipoprotein levels to initial cholesterol-screening tests and evaluate them when selecting drug therapy. The guidelines designate a high high-density lipoprotein level as a factor that reduces the risk of coronary heart disease.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.
